ClinicalTrials.gg

Program

Rabies vaccine

Also written as “rabies vaccine” and “Rabies Vaccine”.

Its studies are mostly in Rabies · Malaria · COVID-19 · Meningitis, Meningococcal, led by 3 companies.

Furthest: phase 3, since Jun 27, 20065 company-led studies, 1 open or runningNext primary completion: Jan 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis30 open or runningphase 3since Jun 27, 2006Jun 27, 2006none ahead
Institut Pasteur10 open or runningno phasesince Mar 31, 2021Mar 31, 2021none ahead
Sinovac Biotech11 open or runningphase 3since May 27, 2025May 27, 2025Jan 30, 2027phase 3 · NCT07055893

Also a collaborator on its studies: Beijing Institute of Biological Products and Changchun Institute of Biological Products.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 27, 2006First study: phase 3 study in RabiesNew to NovartisNovartis · NCT00345319 · 630 enrolled · China
  2. Nov 3, 2011Phase 3 study in Meningococcal InfectionsNovartis · NCT01466387 · 552 enrolled · Czech Republic, Germany
  3. Jun 24, 2014Phase 3 study in Rabies InfectionNovartis · NCT02177032 · 885 enrolled · Philippines, Thailand
  4. Mar 31, 2021Institut Pasteur's first study: no phase study in RabiesNew to Institut PasteurInstitut Pasteur · NCT04829630 · 180 enrolled · Cambodia, Madagascar
  5. May 27, 2025Sinovac Biotech's first study: phase 3 study in RabiesNew to Sinovac BiotechSinovac Biotech · NCT07055893 · 390 planned · Pakistan

Ahead

  1. Jan 30, 2027Primary completion: phase 3 study in RabiesSinovac Biotech · NCT07055893

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Rabies vaccine”name, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07055893Rabies · Pakistan3Not yet recruitingSinovac BiotechJan 30, 2027390
NCT04829630Rabies · Cambodia, Madagascar–CompletedInstitut PasteurFeb 1, 2023180
NCT02177032Rabies Infection · Philippines, Thailand3CompletedNovartisOct 2014885
NCT01466387Meningococcal Infections · Czech Republic, Germany3CompletedNovartisApr 2012552
NCT00345319Rabies · China3CompletedNovartisMay 2006630

How it is read

Names in the registry

  • “Rabies vaccine”, 4 entries
  • “rabies vaccine”, 3 entries
  • “Rabies Vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 14, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.